(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-3-cyclopentyloxy-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835315

PubChem CID: 56670255

Max Phase: Preclinical

Molecular Formula: C30H47N5O11

Molecular Weight: 653.73

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CC[C@H](OC2CCCC2)[C@H]1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI: InChI=1S/C30H47N5O11/c1-14(2)23(31-16(5)36)27(41)32-18(12-21(37)38)26(40)34-24(15(3)4)29(43)35-11-10-20(45-17-8-6-7-9-17)25(35)28(42)33-19-13-22(39)46-30(19)44/h14-15,17-20,23-25,30,44H,6-13H2,1-5H3,(H,31,36)(H,32,41)(H,33,42)(H,34,40)(H,37,38)/t18-,19-,20-,23-,24-,25-,30?/m0/s1

Standard InChI Key: HXMVHUWHZRCCBE-AFIJWPDYSA-N

Molfile:

     RDKit          2D

 46 48  0  0  0  0  0  0  0  0999 V2000
   16.2183  -12.3083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5446  -12.7845    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7888  -13.5735    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.6149  -13.5874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8792  -12.8047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0926  -14.2600    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.7672  -12.5211    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.2343  -11.4837    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.4819  -11.1399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8210   -9.8272    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.4864  -10.3149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1570   -9.8343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9050   -9.0460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0808   -9.0454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6790   -9.8272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3907   -9.4147    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.9631   -9.4147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6790  -10.6522    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.1065   -9.8272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8224   -9.4147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1065  -10.6522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3907  -11.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8224  -11.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5341   -9.8272    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8224   -8.5897    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.2500   -9.4147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9658   -9.8272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2500   -8.5897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9658  -10.6522    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.9658   -8.1772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6825   -8.5908    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.9666   -7.3533    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.6775   -9.4147    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.3934   -9.8272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1051   -9.4147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3934  -10.6522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6775  -11.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1051  -11.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1051   -8.5897    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.7866  -11.5839    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.9384  -10.0885    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.6441   -9.6611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.4033   -9.9770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.9424   -9.3524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5150   -8.6467    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7118   -8.8352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  5  1  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
  9  8  1  0
 10 11  1  0
  1  2  1  0
  2  3  1  0
 15 16  1  0
 15 17  1  0
 15 18  2  0
 16 19  1  0
 19 20  1  0
 19 21  1  6
 21 22  1  0
 21 23  1  0
 20 24  1  0
 20 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  1  1
 27 29  2  0
 28 30  1  0
 30 31  1  0
 30 32  2  0
 27 33  1  0
 33 34  1  0
 34 35  1  0
 34 36  1  6
 36 37  1  0
 36 38  1  0
 35 10  1  0
 35 39  2  0
  3  4  1  0
  9 40  2  0
  4  5  1  0
 12 41  1  6
 11 12  1  0
 41 42  1  0
 42 43  1  0
 12 13  1  0
 13 14  1  0
 14 10  1  0
 11  9  1  1
 43 44  1  0
 44 45  1  0
 45 46  1  0
 46 42  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)

Discover Target: CASP2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CASP3 Tchem Caspase-3 (3632 Activities)

Discover Target: CASP3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 653.73	Molecular Weight (Monoisotopic): 653.3272	AlogP: -1.07	#Rotatable Bonds: 14
Polar Surface Area: 229.77	Molecular Species: ACID	HBA: 10	HBD: 6
#RO5 Violations: 2	HBA (Lipinski): 16	HBD (Lipinski): 6	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26	CX Basic pKa: ┄	CX LogP: -1.31	CX LogD: -4.31
Aromatic Rings: ┄	Heavy Atoms: 46	QED Weighted: 0.12	Np Likeness Score: 0.50

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C.. (2011) Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors., 19 (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors. 2006-03-09 Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors. 2011-10-01 Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. [PMID:21903398]

(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-3-cyclopentyloxy-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source